S'abonner

Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions - 08/12/22

Doi : 10.1016/j.biopha.2022.113977 
Ahmed I. Abulsoud a, b, Hussein M. El-Husseiny c, d, , 1 , Ahmed A. El-Husseiny a, e, Hesham A. El-Mahdy a, Ahmed Ismail a, Samy Y. Elkhawaga a, Emad Gamil Khidr a, Doaa Fathi b, Eman A. Mady f, g, Agnieszka Najda h, , Mohammad Algahtani i, Abdulrahman Theyab i, j, Khalaf F. Alsharif k, Ashraf Albrakati l, Roula Bayram m, Mohamed M. Abdel-Daim m, n, Ahmed S. Doghish o, , 2
a Biochemistry and Molecular Biology Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City 11231, Cairo, Egypt 
b Department of Biochemistry and Biotechnology, Faculty of Pharmacy, Heliopolis University, Cairo 11785, Egypt 
c Laboratory of Veterinary Surgery, Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, 3–5-8 Saiwai Cho, Fuchu-shi, Tokyo 183–8509, Japan 
d Department of Surgery, Anesthesiology, and Radiology, Faculty of Veterinary Medicine, Benha University, Moshtohor, Toukh, Elqaliobiya 13736, Egypt 
e Department of Biochemistry, Faculty of Pharmacy, Egyptian Russian University, Badr City 11829, Cairo, Egypt 
f Laboratory of Veterinary Physiology, Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, 3–5-8 Saiwai Cho, Fuchu-shi, Tokyo 183-8509, Japan 
g Department of Animal Hygiene, Behavior and Management, Faculty of Veterinary Medicine, Benha University, Moshtohor, Toukh, Elqaliobiya 13736, Egypt 
h Department of Vegetable Crops and Medicinal Plants University of Life Sciences, Lublin 50A Doświadczalna Street, 20–280, Lublin, Poland 
i Department of Laboratory & Blood Bank, Security Forces Hospital, P.O. Box 14799, Mecca 21955, Saudi Arabia 
j College of Medicine, Al-Faisal University, P.O. Box 50927, Riyadh 11533, Saudi Arabia 
k Department of Clinical Laboratory sciences, College of Applied medical sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia 
l Department of Human Anatomy, College of Medicine, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia 
m Department of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, P.O. Box 6231, Jeddah 21442, Saudi Arabia 
n Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia 41522, Egypt 
o Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo 11829, Egypt 

Corresponding author at: Laboratory of Veterinary Surgery, Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, 3–5-8 Saiwai Cho, Fuchu-shi, Tokyo 183-8509, Japan.Laboratory of Veterinary Surgery, Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology3–5-8 Saiwai Cho, Fuchu-shiTokyo183-8509Japan⁎⁎Corresponding authors.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

COVID-19 is a worldwide pandemic caused by SARS-coronavirus-2 (SARS-CoV-2). Less than a year after the emergence of the Covid-19 pandemic, many vaccines have arrived on the market with innovative technologies in the field of vaccinology. Based on the use of messenger RNA (mRNA) encoding the Spike SARS-Cov-2 protein or on the use of recombinant adenovirus vectors enabling the gene encoding the Spike protein to be introduced into our cells, these strategies make it possible to envisage the vaccination in a new light with tools that are more scalable than the vaccine strategies used so far. Faced with the appearance of new variants, which will gradually take precedence over the strain at the origin of the pandemic, these new strategies will allow a much faster update of vaccines to fight against these new variants, some of which may escape neutralization by vaccine antibodies. However, only a vaccination policy based on rapid and massive vaccination of the population but requiring a supply of sufficient doses could make it possible to combat the emergence of these variants. Indeed, the greater the number of infected individuals, the faster the virus multiplies, with an increased risk of the emergence of variants in these RNA viruses. This review will discuss SARS-CoV-2 pathophysiology and evolution approaches in altered transmission platforms and emphasize the different mutations and how they influence the virus characteristics. Also, this article summarizes the common vaccines and the implication of the mutations and genetic variety of SARS-CoV-2 on the COVID-19 biomedical arbitrations.

Le texte complet de cet article est disponible en PDF.

Graphical Abstract




ga1

Le texte complet de cet article est disponible en PDF.

Highlights

COVID-19 has triggered a global health crisis that has never been seen before.
The most prevalent mutations were in the S protein and proteins that make up the RdRP.
A wide and diverse range of variants, leading to multiple vaccines production.
Vaccination and global health precautions are critical in COVID-19 prevention.

Le texte complet de cet article est disponible en PDF.

Abbreviations : ACE2, BIBP, CD, CDC, COVID-19, CRP, CTD, E, ELISA, ERGIC, ESR, FP, GCSF, GISAID, GMTs, HCoVs, ICU, Ig, IL, LDH, LNPs, M, MERS-CoV, mRNA, N, NABs, Nsp, NTD, nts, ORFs, PANGOLIN, PCR, pp, r, RBD, RdRP, RDT, RNA, ROCM, S, SARS-CoV, sgRNA, SNP, TAG-VE, TMPRSS2, TNF, VOC, VOHC, VOI, WHO, αCoV, βCoV, γCoV, δCoV

Keywords : SARS-CoV-2, Mutation, Variants, Pandemic disease, Vaccines


Plan


© 2022  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 157

Article 113977- janvier 2023 Retour au numéro
Article précédent Article précédent
  • Editorial Board
| Article suivant Article suivant
  • Effective and economical cell therapy for hair regeneration
  • Jong-Hyuk Sung

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.